tirzepatide cardiovascular risk Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Tirzepatide compared with semaglutide and

In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise

Injection schedules, meal timing, hydration, and symptom patterns may therefore sometimes require closer observation while the body adjusts to treatment

Cummings DE, Purnell JQ, Weigle DS

Practical strategies to minimize retinopathy risk during treatment initiation include: Gradual dose escalation following FDA-approved titration schedules Baseline ophthalmologic assessment before starting therapy in patients with known retinopathy More frequent monitoring during the first year of treatment in high-risk patients Coordinated care between endocrinology and ophthalmology specialists Patient education about vision changes requiring urgent evaluation Consider proactive reduction in insulin or sulfonylurea doses to reduce hypoglycemia risk during treatment intensification Patients should be counseled that while effective glucose control is essential for long-term eye health, any sudden vision changesincluding blurred vision, floaters, flashing lights, or vision losswarrant immediate ophthalmologic evaluation regardless of recent medication changes

Book a consultation with our doctors today and take the first step toward better health and weight management

Table 24 Glycemic Control Outcomes (SEM as First- and Second-Line Therapy